Related Experiment Video
Updated: Jun 2, 2026

Reduced Complications after Arterial Reconnection in a Rat Model of Orthotopic Liver Transplantation
Published on: November 7, 2020
Cardiovascular risk factors after liver transplantation: analysis of related factors
M J Pérez1, D M García, B J Taybi
1Unidad de Hepatología-Trasplante Hepático, Hospital Universitario Carlos Haya, Málaga, Spain. mjimenezp@commalaga.com
Insights
Cardiovascular risk factors (CVRF) are common after liver transplantation. Hepatitis C virus (HCV) infection, especially severe relapse, significantly increases the risk of new-onset diabetes mellitus (DM).
Area of Science:
- Hepatology
- Cardiology
- Transplantation Medicine
Background:
- Cardiovascular risk factors (CVRF) are a significant concern in liver transplant recipients.
- Understanding the interplay between immunosuppression, hepatitis C virus (HCV) infection, and CVRF is crucial for patient management.
Purpose of the Study:
- To analyze the prevalence of CVRF after liver transplantation.
- To investigate the relationship between immunosuppressive agents and CVRF development.
- To determine the impact of HCV infection on CVRF post-transplantation.
Main Methods:
- Retrospective analysis of 158 liver transplants with at least 1-year follow-up.
- Data collection on pre- and post-transplant CVRF including diabetes mellitus (DM), hypertension, hypertriglyceridemia, hypercholesterolemia, and hyperuricemia.
- Assessment of the influence of immunosuppression (tacrolimus vs. cyclosporine) and HCV status on CVRF.
Main Results:
- Hypertension was associated with cyclosporine use (P < .03).
- HCV infection significantly increased the incidence of de novo DM (P < .01).
- Severe HCV relapse showed a 4.4-fold increased risk for de novo DM (P < .03).
Conclusions:
- CVRF commonly develop within the first 3 months post-liver transplantation.
- HCV-positive patients require special attention due to their elevated risk of de novo DM.
- Close monitoring for CVRF is essential in liver transplant recipients, particularly those with HCV.
Aims:
We sought to analyze the cardiovascular risk factors (CVRF) in liver transplantation and their relation to immunosuppression and hepatitis C virus (HCV) infection.
Patients And Methods:
The study included all 158 liver transplants performed between January 2005 and December 2008 that had a minimum follow-up of 1 year. There were 104 men (64%) and 54 women (36%). Data were recorded on both the pretransplant prevalence as well as new cases of diabetes mellitus (DM), hypertension, hypertriglyceridemia, hypercholesterolemia, and hyperuricemia, defined by the need for drug therapy, after a mean follow-up period of 38 months (range, 12-64). We also examined the influence on CVRF of immunosuppression and HCV.
Results:
Tacrolimus was prescribed for 61% of the patients and cyclosporine, 39%. Upon univariate analysis only hypertension was significantly associated with the use of cyclosporine (P < .03). There was a trend to a greater incidence of hypercholesterolemia with cyclosporine (P = .1) and DM with tacrolimus (P = .1). The presence of HCV was significantly associated with a greater incidence of de novo DM (P < .01), as was a severe relapse of hepatitis C (P < .03). Multivariate analysis showed a 4.4 times greater risk for developing de novo DM among patients with a severe relapse of HCV.
Conclusion:
The development of CVRF after liver transplantation was manifested, mainly during the first 3 months posttransplantation. Special attention should be given to the risk for de novo DM among HCV positive patients.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
